Epilepsy Currents, Vol. 15, No. 5 (September/October) 2015 pp. 244-246 © American Epilepsy Society
Current Literature
In Clinical Science
Commentary
An almost universal question to physicians from parents who have a child who experienced a first seizure(s) is some variation of "will my child grow out of his/her seizures?" The question regards prognosis and is laced with the hope that this will be a self-limited condition, disappearing as abruptly and inexplicably as it began. Currently, the most reliable means of answering that question with any degree of certainty is to identify a recognized syndrome that has a known prognosis. (However, it should be recognized that even the best-described syndromes have a range of potential outcomes ranging from seizure freedom to continued seizures with or without cognitive and behavioral co-morbidities.). Despite the existence of an ever-increasing number of syndromes-as described on the International League Against Epilepsy website (http://www.epilepsydiagnosis.org)-a meaningful syndromic diagnosis is not always possible. The clinician is then left to integrate a wide variety of studies from various populations (population-based, referral clinic, hospital), differing lengths of follow-up, and patient-related factors, such as ages of onset, seizure types, cognitive/developmental status, EEG, MRI, and other laboratory findings. Where can guidance be found to provide our families with accurate, if not always comforting, information?
Multiple reports have documented population-based outcomes using a variety of durations of follow-up (cited in the references provided) and criteria for terminal remission (e.g., years since last seizure, whether on or off medication treatment, or both). It is remarkable that the older as well as the newer publications cite seizure-freedom occurring in 60 to 70 percent with lack of remission in the remainder (1) (2) (3) (4) .
It has been only in the last few years that additional important questions regarding outcome have been approached: What are the patterns of remission and relapse over time? What are the risk factors that predict outcome?
The course of epilepsy over time has been addressed in several very recent studies, although appreciated previously (5) . In the same cohort in whom 67% of 144 patients followed for an average of 37 years (recruited 1961-1964) were in termi-
The Course of Childhood-Onset Epilepsy Over the First Two Decades: A Prospective, Longitudinal Study.
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OBJECTIVES: Determine frequency of remissions, relapses, and pharmacoresistance over two decades. Develop a composite measure of seizure control over that time. METHODS: Community-based cohort of children with newly diagnosed epilepsy prospectively followed for up to 21 years with frequent calls and periodic medical record review. Multiple periods of 1-, 2-, 3-, and 5-year remission with subsequent relapses were recorded. Other outcomes included pharmacoresistance (failure of two adequately used drugs), early remission and early pharmacoresistance by 2 years, and complete remission at last contact (CR-LC, 5 years both seizure-and drug-free at last contact). A composite summary of seizure course was created with eight categories ranging from early sustained remission and CR-LC (best) to never achieving a 1-year remission (worst). RESULTS: Five hundred sixteen of 613 participants were followed ≥10 years. An initial 1-2-, 3-, and 5-year remission occurred, respectively, in 95%, 92%, 89%, and 81%. Relapses followed in 52%, 41%, 29%, and 15%, respectively. Repeated remission after relapse was common. Up to seven 1-year, five 2-year and 3-year, and two 5-year remissions were recorded per participant. Pharmacoresistance at any time, early pharmacoresistance (<2 years), early remission, and CR-LC occurred in 118 (22.9%), 70 (13.6%), 283 (54.8%), and 311 (60.3%). Composite outcomes were early sustained remission with CR-LC (N = 172, 33%); later but then sustained remission with CR-LC (N = 51, 10%); one (N = 61, 12%) or more (N = 27, 5%) remission-relapse episodes but then CR-LC; various non-CR-LC outcomes (N = 179, 35%); and never achieved 1-year remission (N = 26, 5%). These patterns varied across groups defined by epilepsy type and presence of brain insults or neurodisability (p < 0.0001). SIGNIFICANCE: The seizure prognosis of pediatric epilepsies is highly variable. Most patients follow complex courses not easily summarized by remission status at the end of a period of follow-up. These complexities may facilitate efforts to understand the impact epilepsy has on young people entering adulthood. nal remission, it was noted that only 23 of the 45 patients who went into remission persisted seizure-free until the last contact (1) . Another 72 patients had a delayed remission (mean 9 years), and 28 achieved remission after one or more relapses. A study from The Netherlands involving 413 adequately treated children (recruited between 1988-1992), divided the outcomes into four patterns: "favorable" (no seizures for 3 years) in 50%, "improving" (not immediate seizure control but remission in the last year) in 29%; "poor" (seizures without remissions), "deteriorating" (initial remission, followed by relapse) in a total of 16%, and "varying" in the remainder. The authors commented on the reality that patients could initially have a course that suggested a seizure-free outcome yet have a late relapse, as well as those who had initially refractory seizures and then entered terminal remission. Further analysis of the Finnish cohort in 2012 revealed that 60% went into remission without relapses (6) . Of the 40% who had relapses, the majority (70%) went into terminal remission.
Etiology appeared to play a role in outcome in The Netherlands study with regard to the percentage of patients having had their last seizure by 10 years after onset: idiopathic (79%), cryptogenic (66%), and remote symptomatic (55%) (3). Other factors that portended a favorable outcome included: few number of seizures, epilepsy type (e.g., benign childhood epilepsy with central-temporal spikes), and rapid response to treatment. In the Finnish studies, only cognitive impairment emerged as a predictor of relapse on multivariate analysis (6) . The authors acknowledged that one of the realities of a 40-year follow-up is the absence of MRI and genetic testing, which may have influenced the predictive capability that goes with a known symptomatic etiology. A subsequent analysis revealed that cognitive impairment, frequency of seizures before and in the year after starting therapy, and idiopathic/symptomatic etiology was predictive of long-term cure (2) .
Recognition that the course of childhood onset epilepsy can be so variable with regard to who will go into terminal remission, significantly complicates advising individual families on whether or not to be more (or less) aggressive (e.g., epilepsy surgery, polytherapies) with regard to further testing and therapeutic options. The challenge is to provide useful information at the time of presentation or shortly thereafter to help guide the family. The recent publication by Berg and Rychilk significantly adds to our understanding of the varying paths a child with epilepsy may take in the two decades following onset of seizures. The power of this report lies in the design (prospective, essentially population-based, new-onset seizures, frequent surveillance by structured questionnaire and review of medical records), as well as in the effort to cluster outcome groups and identification of clinical factors available to the clinician at the time of the patient encounter. The outcome categories are derived from patterns of remission and relapse observed in this community-based population and vary from seizure-free to ongoing seizures with intermediate categories characterized by various degrees of remissions and relapses along a continuum). Groups 1-4 included patients who were seizure-free and off medication. Group 5 differed in that the seizure-free patients were still on medication, and Groups 6 through 8 never entered terminal remission. The implications of the patients who fit into each category are discussed below.
The effort to create meaningful clinical factors for prognosis has two facets. The first essentially condenses the epilepsy syndromes into the most common groups encountered that have implications for outcomes (e.g., "focal self-limited, " composed mainly of benign epilepsy with central-temporal spikes [BECTS], nonsyndromic epilepsy with focal features [NSEF], childhood absence epilepsy [CAE], other genetic generalized epilepsies and encephalopathic epilepsies [e.g., West, Lennox-Gastaut, and Dravet syndromes], and unclassified epilepsies [UNC]). The second distinction separates the patients into those with an "uncomplicated" or "complicated" presentation based upon historical features and suggesting a symptomatic etiology (e.g., history of likely cause of seizures, intellectual disability, abnormal neurological examination, or abnormal MRI).
The results can be put in the categories of expected, pragmatic, and unsettling. In the expected category is the finding that 60% of the total cohort achieved terminal remission (off medication) at last contact (TR-LC), consistent with previous studies. Also expected is that 95% of the FSL and 68% of the CAE groups achieved TR-LC with the encephalopathic epilepsies doing the worst, and the other categories in-between. Thus, making the diagnosis of a well-defined epilepsy syndrome continues to be the best available means of approximating the future. The elegant simplicity of the criteria that distinguished the uncomplicated patients (78% of the population) from the complicated produced a pragmatic result that could help the clinician prepare the family for likely outcomes. Sixty-eight percent of the uncomplicated patients reached TR-LC, whereas only 34% of the complicated group did so. However, this still leaves the possibility that one-third of children with some type of ascertainable neurological injury will be seizure-free in the long term. The unsettling aspect of the report regards the highly variable course of epilepsies in children making prognoses problematic in all but the most clear-cut syndromes. The interaction of the complicated versus uncomplicated presentation, seizure/epilepsy syndrome type, and course of relapses and remission is illustrated in Figure 4 of Berg and Rychilk's manuscript. It demonstrates that achieving the best outcome is not always accompanied by an early and sustained remission. In fact, 139 of 172 patients (81%) who achieved complete remission had one or more relapses, and some did not enter remission until several years after starting therapy. Furthermore, as discussed by the authors, the uncomplicated patients with NSFE were the most likely to be seizure-free on no medication in the long run due to the larger number of that group in the population compared to BECTS.
The question posed by families is, "what is the likelihood of 'my child' becoming seizure free?" Thus, the limitations provided by this study and others highlight the place where population-based epidemiology meets the concept, if not reality, of personalized medicine. The authors emphasize this point in discussing their findings regarding the variable nature of pharmacoresistence through time. Although we may be less confident than previously in predicting long-term outcomes based on short (days, months) or long (years) remissions and relapses, the clinician should never fail to direct therapy based upon the characteristics of each individual patient. Currently, this means pursuing epilepsy surgery in children who have a high likelihood of excellent outcome, including quality of life. Eventually, it will mean pursing treatment options revealed by genomic information.
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